A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With… (NCT00000966) | Clinical Trial Compass
CompletedPhase 1
A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
United States45 participants
Plain-language summary
To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute therapy for toxoplasmic encephalitis in AIDS patients. To assess the toxicity and effectiveness of azithromycin alone as maintenance therapy.
Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus, alternative treatments are needed.
Who can participate
Age range13 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
Concurrent Medication:
Allowed:
* Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP).
* Allowed during maintenance period (weeks 7 - 24):
* Zidovudine and other antiretrovirals available through treatment IND mechanisms, ganciclovir, and maintenance doses of amphotericin (other investigational therapies require permission from the study chair), steroids for the treatment of acute PCP.
* Isoniazid (INH) only for patients already on INH.
Patients must have the following:
* HIV infection or belong to high-risk group. Presumptive or definite diagnosis of toxoplasmic encephalitis.
* Each patient, or his/her appropriate family member, or legal designee must be able to understand and sign a written informed consent, in accordance with the local practices at each site.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
* History of cerebral toxoplasmosis or toxoplasmosis infection in any other organ or tissue.
* Coma.
* More than 72 hours of treatment for current episode of toxoplasmic encephalitis prior to study entry.
* Central nervous system (CNS) lymphoma.
* Cerebral Kaposi's sarcoma.
* Active hepatitis or clinical jaundice.
* History of serious hypersensitivity or intolerance to any of the study drugs.
* Serum or cerebrospinal fluid (CSF) positive for cryptococcus antigen or culture.
* Malignancies requiring use of cytotoxic chemotherapy.
* Inability to take oral…